Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration
Open Forum Infectious Diseases · 03.06.2024 · 11 (6)
DOI: 10.1093/ofid/ofae282 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 25.05.2024. Verfasst von Paula Teichner und 19 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, Janssen Research & Development.
Abstract (Originalsprache)
Background
Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across the phase 3/3b trials, the most frequently reported adverse events were injection site reactions (ISRs).
Methods
We present pooled ISR characteristics and outcomes for participants receiving CAB + RPV LA through week 96 of the FLAIR and ATLAS-2M studies, and survey results from healthcare providers (HCPs) giving injections (eg, injectors) in the ATLAS, FLAIR, and ATLAS-2M studies to determine optimal injection techniques. Surveys were anonymous, self-administered online questionnaires that queried provider demographics, injection experience, and techniques to minimize pre-/postinjection discomfort. Data were summarized using descriptive statistics.
Results
Overall, 8453 ISRs were reported by 801 participants receiving ≥1 injection of CAB LA/RPV LA. Most ISRs were mild to moderate in severity (grade 1–2, 99%), with a median duration of 3 days (interquartile range, 2–4 days), and rarely led to withdrawal (2%). Surveys were completed by 181 HCPs across 113 sites. Pushing the intramuscular injection at slow speed (66%), bringing the medication to room temperature (58%), and relaxing the gluteus muscle before injecting (53%) were ranked as effective preinjection/injection procedure practices for minimizing pain. Most injectors (60%) indicated that a prone position provided optimal patient comfort, and 41% had no preference on injection medication order.
Conclusions
Taken together, the data demonstrate favorable tolerability with CAB + RPV LA injections over the long term and simple techniques routinely used by injectors to help optimize the administration of CAB + RPV LA injections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ViiV Healthcare, Durham, North Carolina, USA.
- ViiV Healthcare, Brentford, United Kingdom.
- ViiV Healthcare, Madrid, Spain.
- Private practice of Franco Felizarta, MD, Bakersfield, California, USA.
- Service de maladies infectieuses et tropicales, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Janssen Research and Development, Beerse, Belgium.
Förderung
- ViiV Healthcare
- Janssen Research & Development
Zitieren
APA
Teichner, P., Chamay, N., Elliot, E., Pascual-Bernáldez, M., Merrill, D., Garris, C., D'Amico, R., Felizarta, C., Torres, E., Van Solingen-Ristea, R., Baugh, B., Patel, P., Vannappagari, V., Dakhia, S., Polli, J. W., Garside, L., Grove, R., Thiagarajah, S., Birmingham, E., & van Wyk, J. (2024). Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration. Open Forum Infectious Diseases, 11(6). https://doi.org/10.1093/ofid/ofae282
Vancouver
Teichner P, Chamay N, Elliot E, Pascual-Bernáldez M, Merrill D, Garris C, et al. Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration. Open Forum Infectious Diseases. 2024;11(6). doi:10.1093/ofid/ofae282
BibTeX
@article{Teichner2024,
author = {Teichner, Paula and Chamay, Nadine and Elliot, Emilie and Pascual-Bernáldez, Miguel and Merrill, Deanna and Garris, Cindy and D'Amico, Ronald and Felizarta, Cecy and Torres, Emma and Van Solingen-Ristea, Rodica and Baugh, Bryan and Patel, Parul and Vannappagari, Vani and Dakhia, Samia and Polli, Joseph W and Garside, Louise and Grove, Richard and Thiagarajah, Shanker and Birmingham, Eileen and van Wyk, Jean},
title = {Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {6},
doi = {10.1093/ofid/ofae282}
}
EUVIMED